{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:01:19Z","timestamp":1792695679233,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Xylazine is an alpha-2 adrenergic agonist approved for veterinary use as a sedative and analgesic for animals. Unfortunately, xylazine has recently become a common adulterant of street drugs in the United States with xylazine-related overdoses and deaths increasing each year. Although the alpha-2 adrenergic antagonist, atipamezole, is an efficacious reversal agent for xylazine that is approved for use in animals, it is not approved for humans. In this study, we aimed to test alternative reversal agents for xylazine, and compare them with atipamezole in a rat model of xylazine-induced unconsciousness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In adult Sprague-Dawley rats, we induced loss of righting reflex (LORR, a surrogate end point for loss of consciousness) with xylazine (5 mg\/kg, intravenous [IV]) and attempted to restore consciousness by administering agents with distinct molecular mechanisms of action: atipamezole (alpha-2 adrenergic antagonist, 200 \u00b5g\/kg IV); d-amphetamine (norepinephrine and dopamine reuptake inhibitor and releasing agent, 1 mg\/kg); chloro-APB (dopamine D1 receptor agonist, 3 mg\/kg IV); and atomoxetine (norepinephrine reuptake inhibitor, 3 mg\/kg IV). Pulse oximetry and heart rate were monitored continuously. After administration of the reversal agents, time to return of righting reflex (RORR) was recorded (n = 12) and animals were assessed with a novel object recognition test (n = 17). One subset of animals underwent surgery to have electroencephalogram (EEG) leads implanted (n = 4). EEG data were recorded after xylazine injection and ensuing administration of a reversal agent and spectral analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      After xylazine-induced unconsciousness, the median time to RORR in atipamezole-, d-amphetamine-, and chloro-APB-treated rats was 1.5 minutes (Interquartile Range [1.0\u20132.0]), 2 minutes (interquartile range [IQR] [1.0\u20133.0]), and 2 minutes (IQR [1.0\u20132.0]) post drug injection, respectively, compared to 56 minutes (IQR [39.5\u201370.5]) after saline control (\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      [4,40] = 41.62,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001). Atomoxetine did not significantly accelerate time to RORR. During the novel object recognition test, all animals spent the same amount of time with the familiar and novel object (range 0\u2013143.5 sec), indicating that no reversal agents restored recognition memory. Xylazine induced an EEG pattern dominated by slow-delta oscillations. Atipamezole, d-amphetamine, and chloro-APB restored EEG oscillations similar to the awake state.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Atipamezole, d-amphetamine, and chloro-APB accelerate emergence from xylazine-induced unconsciousness and restore EEG oscillation patterns consistent with wakefulness. However, none of these reversal agents restore recognition memory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000007589","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:01:54Z","timestamp":1749740514000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats"],"prefix":"10.1213","volume":"142","author":[{"given":"Gwi H.","family":"Park","sequence":"first","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Obert","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Anesthesiology and Intensive Care Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen F.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Solt","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"R1-20260213","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jat\/bkac049","article-title":"Xylazine: pharmacology review and prevalence and drug combinations in forensic toxicology casework.","volume":"46","author":"Kacinko","year":"2022","journal-title":"J Anal Toxicol"},{"key":"R2-20260213","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1021\/acschemneuro.4c00172","article-title":"Classics in chemical neuroscience: xylazine.","volume":"15","author":"Hoffman","year":"2024","journal-title":"ACS Chem Neurosci"},{"key":"R3-20260213","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","article-title":"Xylazine and overdoses: trends, concerns, and recommendations.","volume":"112","author":"Alexander","year":"2022","journal-title":"Am J Public Health"},{"key":"R4-20260213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature.","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"key":"R5-20260213","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","article-title":"Xylazine poisoning: a systematic review.","volume":"60","author":"Ball","year":"2022","journal-title":"Clin toxicol"},{"key":"R6-20260213","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1111\/jdv.19817","article-title":"Necrotic skin ulcerations caused by xylazine in people who inject intravenous drugs.","volume":"38","author":"Oscherwitz","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20260213","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2460\/ajvr.1991.52.08.1265","article-title":"Antagonistic effect of atipamezole on xylazine-induced sedation, bradycardia, and ruminal atony in calves.","volume":"52","author":"Thompson","year":"1991","journal-title":"Am J Vet Res"},{"key":"R8-20260213","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/vr.130.13.268","article-title":"Effects of atipamezole on xylazine sedation in ponies.","volume":"130","author":"Luna","year":"1992","journal-title":"Vet Rec"},{"key":"R9-20260213","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2125.1991.tb05505.x","article-title":"Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers.","volume":"31","author":"Karhuvaara","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"R10-20260213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.1990.tb03748.x","article-title":"Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist\u2014a randomized, double-blind cross-over study in healthy male volunteers.","volume":"30","author":"Karhuvaara","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20260213","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents.","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R12-20260213","doi-asserted-by":"crossref","first-page":"668285","DOI":"10.3389\/fphar.2021.668285","article-title":"D-Amphetamine rapidly reverses dexmedetomidine-induced unconsciousness in rats.","volume":"12","author":"Kato","year":"2021","journal-title":"Front Pharmacol"},{"key":"R13-20260213","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/ALN.0b013e318278c896","article-title":"Activation of D1 dopamine receptors induces emergence from isoflurane general anesthesia.","volume":"118","author":"Taylor","year":"2013","journal-title":"Anesthesiology"},{"key":"R14-20260213","doi-asserted-by":"crossref","first-page":"e0131914","DOI":"10.1371\/journal.pone.0131914","article-title":"Dextroamphetamine (but Not Atomoxetine) induces reanimation from general anesthesia: implications for the roles of dopamine and norepinephrine in active emergence.","volume":"10","author":"Kenny","year":"2015","journal-title":"PLoS One"},{"key":"R15-20260213","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jneumeth.2010.06.020","article-title":"Chronux: a platform for analyzing neural signals.","volume":"192","author":"Bokil","year":"2010","journal-title":"J Neurosci Methods"},{"key":"R16-20260213","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/j.1460-9568.2011.07902.x","article-title":"Computation of measures of effect size for neuroscience data sets.","volume":"34","author":"Hentschke","year":"2011","journal-title":"Eur J Neurosci"},{"key":"R17-20260213","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0022-2496(75)90001-2","article-title":"The area above the ordinal dominance graph and the area below the receiver operating characteristic graph.","volume":"12","author":"Bamber","year":"1975","journal-title":"J Math Psychol"},{"key":"R18-20260213","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/ALN.0000000000003182","article-title":"Spectral and entropic features are altered by age in the electroencephalogram in patients under sevoflurane anesthesia.","volume":"132","author":"Kreuzer","year":"2020","journal-title":"Anesthesiology"},{"key":"R22-20260213","article-title":"Xylazine in drug seizure reports and overdose deaths in the US, 2018-2022.","author":"Cano","journal-title":"medRxiv"},{"key":"R23-20260213","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cca.2021.07.010","article-title":"High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021.","volume":"521","author":"Korn","year":"2021","journal-title":"Clin Chim Acta"},{"key":"R24-20260213","first-page":"142","article-title":"Comparison of atipamezole with yohimbine for antagonism of xylazine in mice anesthetized with ketamine and xylazine.","volume":"56","author":"Janssen","year":"2017","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"R25-20260213","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41386-023-01782-2","article-title":"Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model.","volume":"49","author":"Choi","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"R26-20260213","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1600-0684.2009.00378.x","article-title":"Reversal of ketamine\/xylazine combination anesthesia by atipamezole in olive baboons (Papio anubis).","volume":"38","author":"Langoi","year":"2009","journal-title":"J Med Primatol"},{"key":"R27-20260213","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/vr.128.14.323","article-title":"Reversal of xylazine sedation in dogs.","volume":"128","author":"Jarvis","year":"1991","journal-title":"Vet Rec"},{"key":"R28-20260213","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1467-2995.2011.00625.x","article-title":"Antagonistic effect of atipamezole, flumazenil and naloxone following anaesthesia with xylazine, tramadol and tiletamine\/zolazepam combinations in pigs.","volume":"38","author":"Lu","year":"2011","journal-title":"Vet Anaesth Analg"},{"key":"R29-20260213","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00000542-199809000-00005","article-title":"Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers.","volume":"89","author":"Scheinin","year":"1998","journal-title":"Anesthesiology"},{"key":"R30-20260213","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41380-018-0116-3","article-title":"Treatment strategies for ADHD: an evidence-based guide to select optimal treatment.","volume":"24","author":"Caye","year":"2019","journal-title":"Mol Psychiatry"},{"key":"R31-20260213","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R32-20260213","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuropharm.2009.08.020","article-title":"The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.","volume":"57","author":"Heal","year":"2009","journal-title":"Neuropharmacology"},{"key":"R33-20260213","doi-asserted-by":"crossref","first-page":"585356","DOI":"10.3389\/fphar.2020.585356","article-title":"D-Amphetamine accelerates recovery of consciousness and respiratory drive after high-dose fentanyl in rats.","volume":"11","author":"Moody","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000007589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:27:50Z","timestamp":1786112870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000007589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000007589","relation":{},"ISSN":["0003-2999","1526-7598"],"issn-type":[{"value":"0003-2999","type":"print"},{"value":"1526-7598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}